Editas Medicine Net Income 2015-2021 | EDIT

Editas Medicine net income from 2015 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Editas Medicine Annual Net Income
(Millions of US $)
2020 $-116
2019 $-134
2018 $-110
2017 $-120
2016 $-97
2015 $-73
2014 $-14
Editas Medicine Quarterly Net Income
(Millions of US $)
2021-09-30 $-39
2021-06-30 $-55
2021-03-31 $-57
2020-12-31 $-62
2020-09-30 $8
2020-06-30 $-24
2020-03-31 $-38
2019-12-31 $-38
2019-09-30 $-33
2019-06-30 $-34
2019-03-31 $-29
2018-12-31 $-25
2018-09-30 $-15
2018-06-30 $-39
2018-03-31 $-31
2017-12-31 $-36
2017-09-30 $-27
2017-06-30 $-26
2017-03-31 $-31
2016-12-31 $-39
2016-09-30 $-21
2016-06-30 $-19
2016-03-31 $-18
2015-12-31 $-13
2015-09-30 $-8
2015-06-30 $-48
2015-03-31 $-5
2014-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.512B $0.091B
Editas Medicine, Inc. is a genome editing company. It focuses on translating its genome editing technology into a novel class of human therapeutics which enable precise and corrective molecular modification to treat diseases. Editas Medicine, Inc. is based in Cambridge, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $144.122B 9.11
Bio-Rad Laboratories (BIO.B) United States $18.677B 37.90
QIAGEN (QGEN) Netherlands $11.053B 18.72
Biohaven Pharmaceutical Holding (BHVN) United States $8.002B 0.00
Emergent Biosolutions (EBS) United States $2.809B 10.10
Arcus Biosciences (RCUS) United States $2.516B 0.00
Myovant Sciences (MYOV) United Kingdom $1.432B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.186B 0.00
Zymeworks (ZYME) Canada $0.697B 0.00
Ambrx Biopharma (AMAM) United States $0.230B 0.00
SQZ Biotechnologies (SQZ) United States $0.229B 0.00
Enzo Biochem (ENZ) United States $0.160B 20.69